Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Novel Home Care Device for High-Risk Diabetic Patients (TempTouchRM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Diabetica Solutions Inc..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
Diabetica Solutions Inc.
ClinicalTrials.gov Identifier:
NCT00500175
First received: July 10, 2007
Last updated: July 11, 2007
Last verified: July 2007

July 10, 2007
July 11, 2007
January 2007
Not Provided
incident foot ulcers [ Time Frame: one year ]
Same as current
Complete list of historical versions of study NCT00500175 on ClinicalTrials.gov Archive Site
temperature spikes on foot zones [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
Novel Home Care Device for High-Risk Diabetic Patients
Novel Home Care Device for High-Risk Diabetic Patients

More than half of all lower extremity amputations are in persons with diabetes. These patients suffer from severe, diabetes-induced, peripheral, sensory neuropathy and, thus they frequently do not protect their feet from repetitive shear stress or traumatic episodes and ulceration often ensues. We have previously shown that the temperature profile of the plantar aspects of the foot provides a reliable warning of tissue injury and can be effectively used as a preventive modality. In this study we propose to further develop and clinically test a novel infrared-based temperature instrument (TempTouchRM®) that is intended for home use by high-risk diabetic patients. This step-on remote monitoring device will serve as an early warning system for impending ulcers and Charcot fractures. The study’s central hypothesis is that the TempTouchRM device will reduce the incidence of ulcers by providing an accurate, simple, and effective approach to monitor changes in foot temperatures.

The study’s central hypothesis is that the TempTouchRM device will reduce the incidence of ulcers by providing an accurate, simple, and effective approach to monitor changes in foot temperatures. To study this hypothesis, the following specific aims are proposed:

Aim 1: To develop, validate and implement software and protocols for the following: (i) data acquisition and processing, and (ii) the physician-TempTouchRM communications interface. A state-of-the-art web interface will be developed to allow clinicians to view the stored data for their patients.

Aim 2: To evaluate the effectiveness of the TempTouchRM in reducing the incidence of diabetic foot ulcers among high-risk patients. Our hypothesis is that patients monitored with the TempTouchRM will have fewer foot ulcers and that the ulcers will be less severe. The 110 patient study will comprise two treatment arms: the standard therapy group and the enhanced therapy group The latter will receive standard care plus infrared temperature monitoring using the TempTouchRM daily for 12 months. Elevated temperatures will provide information to the physician that prevention practices should be initiated, such as off-loading, skin care, etc.

Aim 3: To determine the normal range of temperature variations for each individual foot for patients in the Enhanced Therapy and to correlate deviations from this range to the incidence of ulcers. Our previous studies have used the contralateral foot as the control to detect abnormal temperatures. We will investigate the hypothesis that with proper trending of normal foot temperatures, the individual foot can serve as its own control for predicting ulcers.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Diagnostic
  • Diabetes
  • Neuropathic Limb
  • Elevated Temperature
  • Shear Pressure
  • Increased Temperatures
  • Device: TempTouchRM
  • Device: Offloading
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
110
June 2008
Not Provided

Inclusion Criteria:

  • diagnosis of diabetes by WHO criteria, ability to provide informed consent, 18-80 years of age.

Exclusion Criteria:

  • patients with open ulcers or open amputation sites, active Charcot arthropathy, severe peripheral vascular disease, active foot infection, dementia, impaired cognitive function, history of drug or alcohol abuse within one year of the study, or other conditions based on the PI’s clinical judgment.
Both
18 Years to 80 Years
No
Contact: Kevin R HIggins, DPM (210) 657-2644 higgins@xilas.com
Contact: Ruben G Zamorano, MSW, MPH (210) 692-1114 ext 119 zamorano@xilas.com
United States
 
NCT00500175
DK061815
Yes
Not Provided
Diabetica Solutions Inc.
National Institutes of Health (NIH)
Principal Investigator: Kevin R Higgins, DPM
Diabetica Solutions Inc.
July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP